852808-04-9 | Abt-737

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$36.00	$26.00
5mg	98%	in stock	$79.00	$55.00
10mg	98%	in stock	$148.00	$103.00
25mg	≥98%	in stock	$310.00	$217.00
50mg	95%	in stock	$375.00	$262.00
100mg	95%	in stock	$532.00	$372.00
250mg	95%	in stock	$1,103.00	$772.00

Description

• Catalog Number: AC26562
• Chemical Name: Abt-737
• CAS Number: 852808-04-9
• Molecular Formula: C42H45ClN6O5S2
• Molecular Weight: 813.4269
• MDL Number: MFCD12756212
• SMILES: CN(CCC(Nc1ccc(cc1[N+](=O)[O-])S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(CC1)Cc1ccccc1c1ccc(cc1)Cl)CSc1ccccc1)C

Computed Properties

• Complexity: 1320
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 56
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 15
• XLogP3: 9

Literature

• Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.

  The Journal of allergy and clinical immunology 20170801

• CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.

  Oncotarget 20170627

• Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.

  Cell death and differentiation 20161201

• Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.

  Chemico-biological interactions 20160425

• Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.

  International journal of cancer 20150301

• Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.

  Toxicology and applied pharmacology 20140115

• Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.

  Molecular cancer therapeutics 20131001

• Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.

  Proceedings of the National Academy of Sciences of the United States of America 20130827

• ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

  Biochemical pharmacology 20130401

• The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.

  The Journal of biological chemistry 20130308

• N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.

  Leukemia 20121001

• Effect of dual inhibition of apoptosis and autophagy in prostate cancer.

  The Prostate 20120901

• Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.

  Cellular signalling 20120901

• CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.

  Experimental hematology 20120901

• Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk.

  The Journal of biological chemistry 20120810

• Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.

  International journal of molecular medicine 20120801

• Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

  Cell death & disease 20120801

• Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.

  Bioorganic & medicinal chemistry 20120715

• Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

  Journal of medicinal chemistry 20120712

• Bax and Bcl-xL exert their regulation on different sites of the ceramide channel.

  The Biochemical journal 20120701

• Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.

  Oncogene 20120628

• Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.

  Cancer research 20120615

• Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.

  The Journal of biological chemistry 20120615

• Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival.

  Blood 20120614

• Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

  Blood 20120614

• Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.

  Journal of medicinal chemistry 20120614

• Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.

  Leukemia 20120601

• ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.

  The Journal of pharmacology and experimental therapeutics 20120601

• 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.

  Oncogene 20120531

• Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function.

  Blood 20120503

• Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.

  Leukemia 20120501

• ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

  Experimental hematology 20120501

• Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.

  European journal of medicinal chemistry 20120501

• Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.

  Cancer letters 20120428

• A defect in cell death of macrophages is a conserved feature of nonobese diabetic mouse.

  Biochemical and biophysical research communications 20120427

• Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.

  Cell death and differentiation 20120401

• Genetically defining the mechanism of Puma- and Bim-induced apoptosis.

  Cell death and differentiation 20120401

• Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.

  Leukemia 20120401

• MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

  Leukemia 20120401

• Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.

  Apoptosis : an international journal on programmed cell death 20120401

• N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death.

  Nature neuroscience 20120401

• Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.

  Bioorganic & medicinal chemistry 20120401

• Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.

  Cell death & disease 20120401

• Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.

  Molecular cell 20120330

• Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.

  The Journal of biological chemistry 20120323

• Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

  Molecular cancer research : MCR 20120301

• Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.

  Cancer 20120215

• Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.

  Pediatric surgery international 20120201

• p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.

  Apoptosis : an international journal on programmed cell death 20120201

• Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120201

• [The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20120201

• Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

• Calcium homeostasis in vascular smooth muscle cells is altered in type 2 diabetes by Bcl-2 protein modulation of InsP3R calcium release channels.

  American journal of physiology. Heart and circulatory physiology 20120101

• Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.

  Cancer research 20120101

• Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.

  Bioorganic & medicinal chemistry letters 20120101

• Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

  PloS one 20120101

• Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition.

  Leukemia research 20111201

• RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines.

  Neuro-oncology 20111201

• The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.

  Molecular cancer therapeutics 20111201

• Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111115

• Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.

  Blood 20111110

• miR-193b Regulates Mcl-1 in Melanoma.

  The American journal of pathology 20111101

• The two faces of FBW7 in cancer drug resistance.

  BioEssays : news and reviews in molecular, cellular and developmental biology 20111101

• Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.

  Cell death & disease 20111101

• ABT-737 is highly effective against molecular subgroups of multiple myeloma.

  Blood 20111006

• GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.

  Cancer letters 20111001

• Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.

  Journal of leukocyte biology 20111001

• The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

  Experimental hematology 20111001

• Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.

  Pathology 20111001

• Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase.

  Nature cell biology 20111001

• An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

  Blood 20110929

• BH3 mimetics activate multiple pro-autophagic pathways.

  Oncogene 20110915

• ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

• Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.

  Proteins 20110901

• Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.

  Blood 20110811

• Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

  Blood 20110804

• Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.

  Cellular oncology (Dordrecht) 20110801

• Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.

  Cancer research 20110801

• Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.

  The Journal of biological chemistry 20110715

• MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

  Cancer research 20110701

• Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.

  Molecular cancer therapeutics 20110701

• The BH3-mimetic ABT-737 inhibits allogeneic immune responses.

  Transplant international : official journal of the European Society for Organ Transplantation 20110701

• Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.

  Cell death & disease 20110701

• BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.

  Blood 20110630

• The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.

  Molecular pharmacology 20110601

• Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

  Leukemia & lymphoma 20110601

• The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.

  Cell death & disease 20110601

• Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.

  Cancer research 20110515

• The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.

  Biochemical and biophysical research communications 20110506

• 3D-QSAR study on a series of Bcl-2 protein inhibitors using comparative molecular field analysis.

  Protein and peptide letters 20110501

• BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets.

  The Journal of biological chemistry 20110422

• Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.

  Journal of medicinal chemistry 20110324

• Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.

  The Journal of biological chemistry 20110304

• SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.

  Nature 20110303

• The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.

  Cancer chemotherapy and pharmacology 20110301

• Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement.

  Pediatric blood & cancer 20110301

• Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.

  The Journal of clinical investigation 20110301

• Apoptosis induces Bcl-XS and cleaved Bcl-XL in chronic lymphocytic leukaemia.

  Biochemical and biophysical research communications 20110218

• Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.

  Molecular oncology 20110201

• The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.

  Cancer research 20110201

• The BH3 mimetic ABT-737 induces cancer cell senescence.

  Cancer research 20110115

• Bcl-x(L) blocks a mitochondrial inner membrane channel and prevents Ca2+ overload-mediated cell death.

  PloS one 20110101

• Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.

  PloS one 20110101

• The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.

  BMC cancer 20110101

• The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

  PloS one 20110101

• Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.

  PloS one 20110101

• Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

  PloS one 20110101

• MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency.

  American journal of nephrology 20110101

• Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.

  Pediatric blood & cancer 20101201

• Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.

  Molecular cancer therapeutics 20101201

• Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

  Molecular cancer therapeutics 20101201

• Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.

  Blood 20101118

• Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.

  Cancer biology & therapy 20101101

• Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.

  Cancer biology & therapy 20101101

• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  Journal of medicinal chemistry 20101014

• The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

  Hepatology (Baltimore, Md.) 20101001

• Synthesis and biological activities of new di- and trimeric quinoline derivatives.

  Bioorganic & medicinal chemistry 20101001

• Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100901

• Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100815

• The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.

  Journal of immunology (Baltimore, Md. : 1950) 20100815

• Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.

  Leukemia 20100801

• BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.

  Molecular cancer research : MCR 20100801

• Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.

  Journal of computational chemistry 20100730

• Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.

  Cancer research 20100701

• ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

  Molecular cancer therapeutics 20100701

• p53 up-regulated modulator of apoptosis (PUMA) activation contributes to pancreatic beta-cell apoptosis induced by proinflammatory cytokines and endoplasmic reticulum stress.

  The Journal of biological chemistry 20100625

• New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.

  The Prostate 20100601

• Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737.

  Neuropharmacology 20100601

• Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA.

  Pigment cell & melanoma research 20100601

• ARC synergizes with ABT-737 to induce apoptosis in human cancer cells.

  Molecular cancer therapeutics 20100601

• BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.

  Cell death and differentiation 20100501

• Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

  Blood 20100422

• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

  Blood 20100408

• Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.

  Leukemia research 20100401

• Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells.

  Leukemia 20100401

• Bcl-2 antagonists and cancer: from the clinic, back to the bench.

  Cell death & disease 20100401

• The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.

  Molecular pharmacology 20100301

• ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

  Biochemical pharmacology 20100201

• Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L).

  Cell death and differentiation 20100201

• Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.

  Autophagy 20100201

• A small molecule-regulated guanine nucleotide exchange factor.

  Journal of the American Chemical Society 20100127

• Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

  Nature 20100107

• Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.

  The Journal of clinical investigation 20100104

• Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.

  PloS one 20100101

• Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.

  Molecular cancer 20100101

• ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress.

  Cancer chemotherapy and pharmacology 20091201

• [Apoptosis resistance in malignant tumors: novel apoptosis-based therapeutic approaches].

  Der Pathologe 20091201

• BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.

  Hepatology (Baltimore, Md.) 20091201

• The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

  Leukemia 20091101

• Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.

  The Journal of biological chemistry 20091030

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.

  Journal of medicinal chemistry 20091008

• The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice.

  The Journal of clinical investigation 20091001

• Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.

  Molecular pharmacology 20090901

• Bcl-2 modulation to activate apoptosis in prostate cancer.

  Molecular cancer research : MCR 20090901

• Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.

  Cancer biology & therapy 20090801

• Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.

  American journal of respiratory cell and molecular biology 20090701

• Different forms of cell death induced by putative BCL2 inhibitors.

  Cell death and differentiation 20090701

• Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.

  Leukemia & lymphoma 20090701

• The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity.

  Journal of immunology (Baltimore, Md. : 1950) 20090615

• Immunosensitization with a Bcl-2 small molecule inhibitor.

  Cancer immunology, immunotherapy : CII 20090501

• ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.

  Molecular pharmacology 20090501

• Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.

  Nature reviews. Cancer 20090501

• Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

  Cancer research 20090501

• Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

  Blood 20090430

• Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

  Blood 20090423

• BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

  The Journal of investigative dermatology 20090401

• Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

  Molecular cancer therapeutics 20090401

• Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

  Cell death and differentiation 20090301

• Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

  Cancer research 20090301

• Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.

  Blood 20090226

• Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.

  Blood 20090212

• Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

  Journal of cellular physiology 20090101

• RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.

  PloS one 20090101

• Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• Mimicking the BH3 domain to kill cancer cells.

  Oncogene 20081201

• Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

  Journal of medicinal chemistry 20081113

• Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.

  Oncogene 20081106

• Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

  The Journal of clinical investigation 20081103

• Anticancer therapy: boosting the bang of Bim.

  The Journal of clinical investigation 20081103

• Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

  Blood 20081015

• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

  Blood 20081001

• Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

  Cancer research 20081001

• Vitamin D3 induces autophagy of human myeloid leukemia cells.

  The Journal of biological chemistry 20080912

• ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.

  The Journal of biological chemistry 20080905

• Long live the cell death!

  Cell death and differentiation 20080801

• Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.

  Oncogene 20080710

• Essential role for Nix in autophagic maturation of erythroid cells.

  Nature 20080710

• BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.

  Cell cycle (Georgetown, Tex.) 20080701

• [Progress in small-molecule inhibitors of Bcl-2 family proteins].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080701

• Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

  Cell death and differentiation 20080601

• A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

  Cell death and differentiation 20080501

• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

  Cancer research 20080501

• Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

  Journal of the National Cancer Institute 20080416

• BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.

  Cancer research 20080415

• Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.

  Cancer research 20080401

• Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission.

  Journal of neurophysiology 20080301

• BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

  Blood 20080215

• ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

  British journal of haematology 20080101

• Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

  International journal of cancer 20071201

• BH3 mimetics to improve cancer therapy; mechanisms and examples.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20071201

• The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Bcl-2-regulated apoptosis: mechanism and therapeutic potential.

  Current opinion in immunology 20071001

• Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

  PLoS medicine 20071001

• Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

  Blood 20070915

• Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.

  Cell death and differentiation 20070901

• Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.

  Cell death and differentiation 20070901

• BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

  Leukemia 20070801

• BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

  Cancer cell 20070801

• ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

  Leukemia 20070701

• 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

  Oncogene 20070607

• Bcl-2 family proteins are essential for platelet survival.

  Cell death and differentiation 20070501

• Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.

  Journal of medicinal chemistry 20070419

• A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.

  Oncogene 20070405

• Targeting multiple arms of the apoptotic regulatory machinery.

  Cancer research 20070401

• Programmed anuclear cell death delimits platelet life span.

  Cell 20070323

• Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.

  British journal of cancer 20070226

• Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

  Journal of medicinal chemistry 20070222

• Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

  Cancer research 20070201

• Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

  Cancer research 20070115

• The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  The Journal of clinical investigation 20070102

• Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.

  Current topics in medicinal chemistry 20070101

• Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

  Cell cycle (Georgetown, Tex.) 20061201

• Restoring cancer's death sentence.

  Cancer cell 20061101

• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  Cancer cell 20061101

• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  Cancer cell 20061101

• A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

  Cancer research 20060901

• Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

  Cancer cell 20060501

• Emerging drugs for chronic lymphocytic leukaemia.

  Expert opinion on emerging drugs 20060301

• [New hope for the cancer patient?].

  Pharmazie in unserer Zeit 20060101

• Targeting mitochondria emerges as therapeutic strategy.

  Journal of the National Cancer Institute 20051221

• Defects of the apoptotic pathway as therapeutic target against cancer.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20051201

• BCL-2: found bound and drugged!

  Trends in molecular medicine 20051001

• Killing cancer cells by flipping the Bcl-2/Bax switch.

  Cancer cell 20050701

• An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

  Nature 20050602

• Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.

  Hematology. American Society of Hematology. Education Program 20050101

• Subversion of the Bcl-2 life/death switch in cancer development and therapy.

  Cold Spring Harbor symposia on quantitative biology 20050101

• A matter of life and death.

  Cancer cell 20020201

• An informatics approach identifying markers of chemosensitivity in human cancer cell lines.

  Cancer research 20001101